Loading
A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05502237, led by Gilead Sciences with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumour Aberrations. Planned enrolment is 1021 participants (actual). The study started in 2022-10-12 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.
Shares Domvanalimab, Non-small-cell lung cancer.
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
Shares Domvanalimab, Gilead Sciences (incl. Kite).
Shares Gilead Sciences (incl. Kite), PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
Shares Domvanalimab, PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer.
Shares Domvanalimab, Gilead Sciences (incl. Kite).